Last reviewed · How we verify
normal saline plus hyruan
Normal saline combined with hyaluronic acid (Hyruan) provides hydration and viscoelastic lubrication to tissues.
Normal saline combined with hyaluronic acid (Hyruan) provides hydration and viscoelastic lubrication to tissues. Used for Dry eye syndrome, Ocular surface lubrication, Joint lubrication and protection.
At a glance
| Generic name | normal saline plus hyruan |
|---|---|
| Also known as | normal saline plus hyaluronic acid |
| Sponsor | Taipei Medical University |
| Drug class | Viscoelastic agent / Lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Orthopedics |
| Phase | FDA-approved |
Mechanism of action
This combination uses normal saline as a physiologic carrier solution paired with hyaluronic acid, a naturally occurring polysaccharide that provides viscosity and tissue protection. Hyaluronic acid acts as a lubricant and hydrating agent, commonly used in ophthalmic and orthopedic applications to reduce friction and maintain moisture in affected tissues.
Approved indications
- Dry eye syndrome
- Ocular surface lubrication
- Joint lubrication and protection
Common side effects
- Mild ocular irritation
- Temporary blurred vision
- Allergic reaction
Key clinical trials
- Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis (PHASE4)
- Verification of the Efficacy/Safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (PHASE1, PHASE2)
- Is Combined Steroid and Sodium Hyaluronate Hydrodilatation More Effective Than Isolated Steroid Hydrodilatation in Treating Patients With Adhesive Capsulitis (NA)
- Effects of Knee Injections on Patients With Knee Osteoarthritis (PHASE4)
- Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |